Our new website is coming soon, give it a try now and let us have your feedback. Take me to the Beta



Register
Login:
Share:
Email Facebook Twitter

TSX Lithium explorer International Lithium Corp prepares to drill at Raleigh Lake Watch Now

TSX Lithium explorer International Lithium Corp prepares to drill at Raleigh Lake
Exclusive: Hardman & Co Investor Forum - Severn Trent, Calculus Capital, Volta Finance, Residential


Glaxosmithkline Share News (GSK)

Stock Market news at lse.co.uk - RSS News Feeds

Share News for Glaxosmithkline (GSK)


Share Price: 1,584.40Bid: 1,587.00Ask: 1,587.20Change: 0.00 (0.00%)No Movement on Glaxosmithkline
Spread: 0.20Spread as %: 0.01%Open: 1,567.00High: 0.00Low: 0.00Yesterday’s Close: 1,584.40




UPDATE 1-GSK's 3-in-1 inhalable drug shows promise in asthma study

Thu, 2nd May 2019 18:41

(Adds background on market opportunity)

May 2 (Reuters) - British drugmaker GlaxoSmithKline Plc said on Thursday that its three-in-one drug Trelegy met the main goal of a late-stage asthma study, signalling a possible boost to its lung medicines division that has been hit by generic competition.

The company, along with co-developer Innoviva Inc, said the once-daily inhaler improved lung function in patients with uncontrolled asthma, compared to its other medicine Relvar/Breo Ellipta.

However, GSK said Trelegy Ellipta did not meet its secondary goal of showing a reduction in the rate of exacerbations.

"We plan to submit these data for regulatory review after the full dataset is available," said GSK's Chief Scientific Officer Hal Barron.

The results come at a time when GSK is hit by generic competition for its blockbuster asthma treatment Advair and it looks to newer respiratory drugs to make up for declines in older medicines.

Trelegy Ellipta is already approved for treatment of chronic obstructive pulmonary disease (COPD), a condition that limits airflow to the lungs.

The drug became the first once-daily triple medicine for COPD when U.S. regulators gave it the green light in late 2017, putting GSK ahead of rivals such as AstraZeneca and Novartis.

More than 30 percent of asthma patients cannot fully restore their lung functions with two-drug inhalable combinations such as GSK's Breo, creating a market opportunity for a more powerful combination therapy.

Trelegy, delivered through GSK's inhaler Ellipta, generated 156 million pounds ($203 million) in sales last year, from its use against chronic obstructive pulmonary disease (COPD), or smokers' lung.

Analysts at HSBC project 1.4 billion pounds in Trelegy revenue by 2023, also helped by future use against asthma, though COPD will likely remain the larger commercial opportunity.

(Reporting by Pushkala Aripaka in Bengaluru and Ludwig Burger in Frankfurt; Editing by Maju Samuel and Elaine Hardcastle)



(c) Copyright Thomson Reuters 2019. Click For Restrictions - https://agency.reuters.com/en/copyright.html


Related Shares:





Germany's Stada buys six of GSK's consumer brands, eyes further deals

FRANKFURT, June 7 (Reuters) - Private equity-backed generic drugmaker Stada said on Friday it would buy six consumer healthcare products from British
[7 Jun '19 09:01]

Trump strikes "supportive" tone in meeting with British business leaders -sources

By Lawrence White and Siddharth CavaleLONDON, June 4 (Reuters) - U.S. President Donald Trump struck a positive, conciliatory tone with top British and
[4 Jun '19 15:09]

UK cross-border M&A activity slumps in early 2019

LONDON, June 4 (Reuters) - The value of cross-border company takeovers in Britain fell sharply in the first three months of 2019 as the number of acqu
[4 Jun '19 09:36]

UPDATE 2-FTSE 100 higher as trade respite lifts banks, miners

* FTSE 100 up 0.4%, FTSE 250 up 0.7%* Banks, miners top boosts* Hargreaves Lansdown down after fund suspended* Retailers hit after consumer spending s
[4 Jun '19 09:26]

GSK's Nucala wins European panel thumbs-up for self-administration

June 4 (Reuters) - GlaxoSmithKline said on Tuesday it had won marketing approval from a European Medicines Agency (EMA) panel for its Nucala drug to b
[4 Jun '19 08:20]

Let's deepen economic ties, Britain's May tells Trump

LONDON, June 3 (Reuters) - British Prime Minister Theresa May will call on U.S. President Donald Trump to deepen transatlantic economic cooperation on
[3 Jun '19 22:30]

UPDATE 2-Pharma stocks aid turnaround in FTSE 100; profit alert sinks Kier

* FTSE 100 up 0.3%* FTSE 250 down 0.5%* Pharma, consumers biggest boosts to main index* Kier at 2 decade low after profit alert (Adds company news ite
[3 Jun '19 09:12]

UPDATE 1-Lynparza stalls pancreatic cancer in patients with BRCA mutations -study

(Adds comments from AstraZeneca executive, PIX available)By Julie SteenhuysenCHICAGO, June 2 (Reuters) - AstraZeneca and Merck & Co's Lynparza helped
[2 Jun '19 18:10]



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.